| Summary: | Omalizumab, the blockbuster monoclonal antibody anti-IgE that revolutionized the market by
the disruptive innovation that supposed more than 20 years ago. This biological drug changed
the paradigm of the treatment of allergic diseases, particularly severe allergic asthma and
chronic spontaneous urticaria. It opened up a new alternative world of possible treatments,
covering the clinical unmet needs of asthmatic patients and creating value for patients who do
not respond well to traditional medicines (small-molecules). Its efficacy and safety have been
demonstrated in numerous clinical trials and Real-World Evidence. These observations have
favoured the life cycle management of the product for new applications, including nasal
polyposis and food allergies. However, it is no longer the only biological on the market for the
treatment of these pathologies, so how is it possible that after so many years it is still a blue
ocean product?
|
|---|